MIMS Group, a leading Asia-Pacific provider of healthcare technology, is accelerating product innovation and international growth. The company has reshaped its businesses and leadership structure to support its next phase of growth, following the appointment of Sohil Goswami as Group CEO in January 2026. With six decades of trusted medical data and expertise, MIMS is transforming its healthcare data, content, and market expertise into new technology platforms, customer applications, and services.
MIMS has launched MIMS Pulse, its next-generation Clinical Decision Support platform, which combines medicines data and clinical knowledge with modern technology and flexible deployment capabilities. The company is also scaling eMIMS Plus, a platform that brings trusted medicines information into a modern digital experience. eMIMS Plus was first launched in Australia and is now available in India and Malaysia, with plans to expand across Southeast Asia.
MIMS is developing its global Clinical Decision Support offering, building on MIMS Pulse and eMIMS Plus to take its clinical data and technology capabilities into new markets and customer environments. The company is also expanding its Medical Communications business internationally, with commercial capabilities in the US and UK. This expansion creates opportunities with new client segments and global life sciences organisations.
MIMS' Medical Communications business is transforming for global growth, developing digital events, AI-enabled content capabilities, and new customer engagement models. The company is exploring more connected, intelligence-led services to help healthcare and life sciences organisations better understand their markets, engage healthcare professionals, and make informed decisions.
According to Sohil Goswami, MIMS is transforming its foundation into the next generation of digital products, platforms, and services. The company has been reshaping its business, strengthening its technology, and building new ways to serve customers across markets. Goswami emphasised that MIMS' opportunity is to turn trusted medical data, deep healthcare relationships, and market knowledge into the next generation of products, platforms, and services.
MIMS is present in 17 markets globally, with over two million healthcare professional subscribers to its drug and resource portal, digital and print publications. The company combines healthcare communications expertise with established networks and presence in the Asian healthcare community, enabling clients to engage their stakeholders in meaningful dialogue through medical and marketing communications services.
MIMS has offices in various global markets, including Singapore, Australia, China, Germany, and Hong Kong SAR. The company facilitates long-term placement of nurses, pharmacists, and doctors across the globe to match the demands of healthcare institutions looking for high-calibre practitioners. With its established strengths and new products, MIMS is poised to compete and grow globally while staying relevant to the markets it serves.
Key points
- MIMS Group accelerates product innovation and international growth with new products, market expansion, and AI-enabled capabilities.
- The company has launched MIMS Pulse and is scaling eMIMS Plus to support safer and more efficient clinical workflows.
- MIMS is present in 17 markets globally, with over two million healthcare professional subscribers to its drug and resource portal, digital and print publications.
